Propanc Biopharma News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

28.07.20	Propanc Biopharma Receives Investment from Institutional Investor (Businesswire)
11.05.20	Propanc Biopharma Provides Shareholder Update (Businesswire)
16.04.20	How Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are Increasingly Vulnerable to the COVID-19 Global Pandemic (Businesswire)
14.04.20	Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office (Businesswire)
31.03.20	Propanc Biopharma Enters Into a $3 Million Financing with Institutional Investor (Businesswire)
16.03.20	Propanc Biopharma’s Scientific Advisory Board Member Promoted to Professorship Position at Jaén University, Spain (Businesswire)
18.11.19	Propanc Biopharma Advances POP1 Drug Discovery Program (Businesswire)
29.10.19	Propanc Biopharma Provides Shareholder Update and Forecast for 2020 (Businesswire)
21.10.19	Propanc Biopharma Illustrates Novel Mode of Action of PRP, Suppressing EMT Pathways and Metastasis in Cancer Patients (Businesswire)
21.08.19	Propanc Biopharma Receives Granted US Patent Covering Additional Composition Claims for PRP (Businesswire)
12.08.19	Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Cancer Stem Cell Effects of Proenzymes (Businesswire)
08.08.19	Propanc Biopharma Completes Development of Bio-analytical Assay Method to Quantify PRP’s Active Ingredients in Preparation for First-In-Human Study (Businesswire)
15.07.19	Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split (Businesswire)
27.06.19	Propanc Biopharma’s Intellectual Property Portfolio Undergoes Rapid Growth (Businesswire)
24.06.19	Propanc Biopharma Appoints Carlo Campiciano as Chief Financial Officer (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	606.00	1.41 %	K V
Logitech Intl	89.42	0.90 %	K V
Zurich Insur Gr	557.00	0.69 %	K V
ABB	49.35	0.65 %	K V
Swiss Re	139.30	0.32 %	K V
Novartis	95.59	-0.52 %	K V
Swisscom	506.00	-0.78 %	K V
Kuehne+Nagel Int	201.60	-0.79 %	K V
Sonova Hldg	305.20	-3.42 %	K V
UBS Group	29.55	-7.05 %	K V